Rheumatology Winter Clinical Symposium

08/13/2025

RA often leads to ILD—but not the other way around. New insights clarify that while 30–40% of RA patients develop lung complications, ILD doesn’t trigger RA.

Rheumatoid arthritis is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

08/11/2025

A new NEJM review by Sandborg et al. breaks down juvenile idiopathic arthritis—covering classification, biology, genetics, clinical features & treatment progress.

Sandborg et al. has published an overview of juvenile idiopathic arthritis (JIA) - its classification, biology, genetics, , clinical presentations and treatment advances in the New England Journal of Medicine (NEJM).JIA is the most common form of inflammatory arthritis in the pediatric population an...

08/09/2025

Do you have a rheumatology question or case for Dr. Cush? Record it today and you might be featured in an upcoming podcast episode!

Record a Question or Comment... Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.

08/07/2025

Just released: 2025 BSR guidelines for managing ANCA-associated vasculitis (GPA, MPA & EGPA) offer updated, evidence-based care recommendations for adult patients.

The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) have published a guideline for the management of adults with ANCA-associated vasculitis (AAV); specifically three conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and....

07/31/2025

Rheumatology’s best minds meet on Maui at RWCS 2026. Learn, connect, and recharge Feb 11–14. Don’t miss this world-class event—in person or online. Register today: https://buff.ly/muYqnrj

07/13/2025

RWCS isn’t just another meeting—it’s THE premier academic rheumatology event. Join us for deep dives, lively discussions, and Maui sunsets. Register now for 2026: https://buff.ly/muYqnrj

07/11/2025

JAKs vs CV risk? EULAR 2025 brings new hope with CPL’116 showing promise in phase 2. Could pairing JAKs with cardioprotection finally rock the boat? The Lancet Rheumatology weighs in.

JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might hav...

07/09/2025

Pregnancy in SLE goes beyond clinical risks. New EULAR 2025 findings highlight how social determinants of health can impact outcomes. Are we addressing the full picture?

While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes.

07/07/2025

RA and the nervous system are more connected than we thought. Neuromodulation may hold new answers in inflammation control. Is this the next frontier in RA care? https://buff.ly/OIBHOUR

Over the last 50 years, discoveries of connections between inflammation and the nervous system have been better understood.

07/05/2025

Braces, water therapy, and exercise lead the way in non-drug treatments for knee OA. A new meta-analysis highlights their power.

Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.Knee osteoarthritis (KOA) ...

07/03/2025

Think RA care is complete with b/tsDMARDs? Think again. What more can we do for patients with very early arthritis?

It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treat...